Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Nov 29 2017

• By Emily Hayes

3d render illustration of human digestive system - front view

Related Content

FDA Approval Round Up: Keytruda, Opdivo Add Claims

Sep 25 2017

FDA's NDA And BLA Approvals: Radicava, Minolira, Bavencio

May 12 2017

Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial

May 10 2017

Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer

Mar 24 2017

Merck KGaA Highlights Mavenclad Advances In Tough Quarter

Nov 10 2017

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Jul 25 2017

Related Companies

Merck KGaA

Pfizer Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Ono Pharmaceutical Company, Ltd.

Roche Holding AG

Additional Topics

ImmunoOncology Clinical Trials Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window